A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, in combination with docetaxel, and in combination with paclitaxel.
Advanced Solid Tumors
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, in combination with docetaxel, and in combination with paclitaxel.
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
-
Mayo Clinic Jacksonville, Jacksonville, Florida, United States, 32224
Florida Cancer Specialists, Sarasota, Florida, United States, 34232
Moffitt Cancer Center, Tampa, Florida, United States, 33612
Mayo Clinic Rochester, Rochester, Minnesota, United States, 55905
Sarah Cannon Research Institute, Nashville, Tennessee, United States, 37203
MDACC, Houston, Texas, United States, 77030
NEXT Dallas, Irving, Texas, United States, 75039
NEXT Virginia, Fairfax, Virginia, United States, 22031
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Vividion Therapeutics, Inc.,
2027-12-31